Blog
RSS FeedPosted by Michael Wonder on 28 Mar 2019
Promising lung cancer treatment approved for Cancer Drugs Fund
28 March 2019 - A promising new lung cancer treatment will be available on the NHS through the Cancer Drugs Fund, ...
Posted by Michael Wonder on 27 Mar 2019
NICE recommendation for Steglatro in type 2 diabetes mellitus
27 March 2019 - NICE has recommended MSD’s Steglatro (ertugliflozin) for use within the NHS, for the treatment of adults ...
Posted by Michael Wonder on 23 Mar 2019
NICE nod for Takeda’s Adcetris in advanced stage CTCL
22 March 2019 - Takeda has announced the NICE recommendation of its advanced cutaneous T-cell lymphoma drug Adcetris (brentuximab vedotin). ...
Posted by Michael Wonder on 19 Mar 2019
NICE wants to stop saying ‘no’ – but needs pharma’s co-operation
18 March 2019 - Suggests Orkambi row has undermined confidence in NICE process. ...
Posted by Michael Wonder on 12 Mar 2019
NICE u-turn backs use of Darzalex combo for myeloma relapse
12 March 2019 - Myeloma patients in England are set to gain NHS access to a new second-line treatment combination ...
Posted by Michael Wonder on 11 Mar 2019
NICE nod for Almirall's Ilumetri, UCB's Cimzia
11 March 2019 - The NICE has recommended Almirall's Ilumetri and UCB's Cimzia as a treatment options for severe plaque ...
Posted by Michael Wonder on 11 Mar 2019
NICE provisionally approves Almirall's Ilumetri (tildrakizumab), as a cost effective option for adults with moderate-to-severe plaque psoriasis
8 March 2019 - Final NICE approval is expected in April 2019. ...
Posted by Michael Wonder on 22 Feb 2019
NICE says drug to treat Batten disease cannot be recommended for NHS use because company is unable to address concerns about long-term effectiveness
22 February 2019 - NICE has published draft guidance which confirms its earlier decision not to recommend cerliponase alfa (also called ...
Posted by Michael Wonder on 16 Feb 2019
Alunbrig recommended by NICE for non-small-cell lung cancer
15 February 2019 - NICE has recommended the use of Alunbrig (brigatinib) for treating ALK-positive advanced non-small-cell lung cancer after ...
Posted by Michael Wonder on 15 Feb 2019
NICE draft guidance recommends pertuzumab for new breast cancer indication after improved price offer from company
15 February 2019 - NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in ...
Posted by Michael Wonder on 01 Feb 2019
NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma
1 February 2019 - Adults with relapsed or refractory diffuse large B-cell lymphoma will be able to access another revolutionary chimeric ...
Posted by Michael Wonder on 18 Jan 2019
NICE OK for Bravtovi skin cancer drug
18 January 2019 - NICE has recommended Pierre Fabre’s Bravtovi (encorafenib) and Mektovi (binimetinib) combination as an option for some ...
Posted by Michael Wonder on 18 Jan 2019
Thousands of adults with chronic lymphocytic leukaemia to benefit from new treatment option
18 January 2019 - Thousands of people will benefit as NICE recommends venetoclax with rituximab for adults with relapsed or refractory ...
Posted by Michael Wonder on 17 Jan 2019
NICE approval for Verzenios in metastatic breast cancer
17 January 2019 - NICE has recommended Eli Lilly’s Verzenios (abemaciclib) in combination with an aromatase inhibitor as treatment option ...
Posted by Michael Wonder on 10 Jan 2019
NICE publishes final guidance on another use of Keytruda for patients with NSCLC
10 January 2019 - This time it is for patients with untreated, metastatic non-squamous non-small cell lung cancer. ...